Yang Sen and Bristol-Myers Squibb join forces to develop a new generation of anticoagulant
Yang Sen and Bristol-Myers Squibb join forces to develop a new generation of anticoagulant
April 20, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Bristol-Myers Squibb (BMS) recently announced that it will work with Johnson & Johnson's Janssen on a global partnership program for Factor XIa (FXIa) inhibitors. The program includes the development and promotion of Bristol-Myers Squibb's FXIa inhibitor BMS-986177, a research-based anticoagulant compound, for the prevention and treatment of major thrombotic diseases. It is expected that BMS-986177 will be introduced into Phase 2 clinical trials in the second half of 2018 to study the prevention of secondary stroke. Janssen will pay a prepayment to Bristol-Myers Squibb, as well as potential development and regulatory milestones.
Thrombotic diseases, including cardiovascular diseases such as coronary artery disease, stroke and peripheral arterial disease, can prevent diseases caused by blood clots by using anticoagulants. The greatest risk of anticoagulant therapy is an increased risk of bleeding. In other healthy populations, the risk of bleeding increases little, but the risk of bleeding in patients who have recently undergone surgery, cerebral aneurysms, and other diseases is extremely high.
This collaboration will be based on the FXIa study of patients with hemophilia C before Bristol-Myers Squibb. Bristol-Myers Squibb claims that FXIa plays a key role in activating and expanding the coagulation cascade through intrinsic pathways. In a small study of patients with hemophilia C (without FXIa), they found that these patients had a lower risk of stroke and therefore developed the idea of ​​using it as a potential antithrombotic pathway. It is understood that patients with hemophilia C have almost no adverse bleeding in the absence of major injury or surgery. Conversely, elevated levels of FXI/FXIa are risk factors for stroke and venous thromboembolism.
FXIa is a key factor involved in the amplification of procoagulant signals. Because it reduces the risk of bleeding, it is considered to be an important target for anticoagulant drug research. Janssen and Bristol-Myers Squibb said that the goal of the next generation of anticoagulants such as BMS-986177 is to demonstrate similar or higher efficacy than current standards of care, while reducing the risk of bleeding in patients. Early clinical studies have shown that FXIa inhibitors have the potential to reduce the risk of thrombotic events, and the risk of bleeding is significantly reduced compared to currently available treatments.
â–² FXIa is a key factor involved in the amplification of procoagulant signals. (Source: Bristol-Myers Squibb official website)
Dr. Tom Lynch, Executive Vice President and Chief Scientific Officer of Bristol-Myers Squibb, said: "At Bristol-Myers Squibb, we are rooted in our commitment to people with cardiovascular disease. We are proud to work with Janssen to advance cutting-edge science. Develop and develop new treatment options such as BMS-986177 for the treatment of severe cardiovascular disease. By combining our extensive expertise in the development and promotion of cardiovascular therapy, we can maximize the potential for FXIa inhibition."
“With the addition of the FXIa Inhibitor Program, Janssen will continue to work tirelessly to provide true conversion therapy to patients worldwide. Through this new collaboration, we are likely to improve the treatment of patients with cardiovascular disease characterized by thrombosis. Standard." Dr. Mathai Mammen, Global Head of Research and Development at Yangsen, said in a statement.
We look forward to combining the advantages and extensive expertise of the two major companies in cardiovascular therapy to maximize the potential of FXIa inhibitors and bring new anticoagulant options to patients with thrombotic diseases. patient!
Reference materials:
[1] Janssen, Bristol-Myers Squibb Team Up to Develop Therapy
[2] Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Potential Next-Generation Cardiovascular Therapy
[3] Bristol-Myers Squibb's official website
[4] Factor XIa inhibitors: A review of the patent literature
Digital Imaging Equipment,X-Ray Equipment And Accessories,16 Slice Ct Scan,Ct Scanner
Shanghai Rocatti Biotechnology Co.,Ltd , https://www.ljdmedicals.com